Evidence map›Paper›PMID 41364004›Full record

ArticleJournal of virology2026

Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.

Qi Yang, Bao Xue, Xianjie Qiu, Kaixin Yang, Jielin Tang, Anqi Zhou, Jingjing Zou, Yuhan Mao, Jiayi Zhong, Yuan Zhou and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Qi Yang *Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.ORCID 0009-0009-1648-4189
Bao Xue *Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Xianjie Qiu *Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Kaixin Yang *Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Jielin Tang *Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Anqi ZhouGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Jingjing ZouGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.ORCID 0009-0005-9682-2328
Yuhan MaoGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Jiayi ZhongGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Yuan ZhouGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Wei ZhangGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Qiong ZhangGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.ORCID 0000-0001-9790-3625
Qingyu XiaoGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.
Wei TangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, Guangdong, P.R. China.
Zhiyu LiDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
Wencai YeState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, Guangdong, P.R. China.
Gang ZouShanghai Ark Biopharmaceutical Co., Ltd, Shanghai, P.R. China.
Wei PengGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.ORCID 0000-0002-0949-4487
Jinsai ShangGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.ORCID 0000-0001-8164-1544
Xi XuDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.ORCID 0000-0002-1306-7373
Yixue LiGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.ORCID 0000-0002-1198-7176
Xinwen ChenGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, P.R. China.ORCID 0000-0002-4052-8155

Funding

Major Project of Guangzhou Laboratory GZNL2024A01010Major Project of Guangzhou Laboratory SRPG22-002National Natural Science Foundation of China 32470168National Natural Science Foundation of China 82103989Natural Science Foundation of Guangdong Province 2024A1515011589Peal River Talent Recruitment Program 2019CX01Y422
6 · The paper itself

Abstract

Lonafarnib, an oral antiviral that targets the fusion glycoprotein of respiratory syncytial virus (RSV), has demonstrated efficacy

Indexed as

Antiviral AgentsDrug Resistance, ViralPyridinesRespiratory Syncytial Virus, HumanViral Fusion ProteinsCysteineHumansMolecular Dynamics SimulationMutationRespiratory Syncytial Virus InfectionsAntiviral AgentsCysteinePyridinesViral Fusion Proteinsfusion glycoproteinlonafarnibproteolysis-targeting chimeraresistant mutationsrespiratory syncytial virus

Identifiers

PMID41364004
PMCPMC12817919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.